glp 1 agonists for alcohol use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance disorders: An emerging pharmacotherapeutic target glp 1 for alcohol use

Clinical studies on neuroprotection of GLP-1RAs After numerous preclinical studies have examined the neuroprotective effects of GLP-1RAs, new clinical trials have been initiated

Vidal, J., Flores, L., Jimnez, A., Pan, A

Sources Endocrine Society Consuming more protein may protect patients taking an anti-obesity drug from muscle loss endocrine.org University of Utah Health Want to Lose Weight

If the phase 2b trial goes well, its possible the company could trial the combination of bimagrumab and tirzepatide or another one of the GLP-1 agonists in its pipeline

In a recent review of GLP-1 RA patient preferences, important attributes driving patient choice included dose frequency, device characteristics (including type of device and needle size), change in HbA1c, and adverse event profile [124]

45,46 As shown in Figure 2 , GLP-1RAs penetrate the blood-brain barrier and directly activate GLP-1 receptors in the hypothalamus, especially within the ARH nucleus, a key center for appetite regulation